Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Analysts

Spyre Therapeutics, Inc. (NASDAQ:SYRE) has received a consensus rating of “Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $43.17.

Several brokerages recently weighed in on SYRE. Robert W. Baird began coverage on Spyre Therapeutics in a report on Thursday, May 2nd. They issued an “outperform” rating and a $50.00 price objective for the company. Stifel Nicolaus boosted their price objective on Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. BTIG Research boosted their price objective on Spyre Therapeutics from $32.00 to $40.00 and gave the company a “buy” rating in a report on Friday, May 10th. Finally, Wells Fargo & Company boosted their price objective on Spyre Therapeutics from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, May 13th.

Spyre Therapeutics Stock Performance

Shares of NASDAQ SYRE opened at $32.98 on Friday. Spyre Therapeutics has a 1 year low of $2.66 and a 1 year high of $47.97. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -0.46 and a beta of 2.93. The stock’s 50-day simple moving average is $36.23.

Spyre Therapeutics (NASDAQ:SYRE) last announced its earnings results on Monday, May 13th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, research analysts expect that Spyre Therapeutics will post -3.21 EPS for the current fiscal year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).